Urinary biomarkers IGFBP7 and TIMP-2 in the ICU: a multicenter prospective study on acute kidney injury outcomes - 14/07/26
, Antoni Jordi Betbesé-Roig a, ⁎ , José Alberto Santos-Rodríguez a, Xosé Luis Pérez-Fernández b, Joan Sabater-Riera b, Javiera Puentes-Yáñez b, Teresa María Tomasa-Irriguible c, Ana Campos-Gómez c, Ricard Ferrer d, Marcos Pérez-Carrasco d, Yolanda Díaz-Buendía e, Rosana Muñoz-Bermúdez e, Mireia Cuartero-Sala fNephroprotect Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
Acute kidney injury (AKI) is prevalent in critically ill patients, contributing to high morbidity, mortality, and healthcare costs. Early detection and differentiation between transient and persistent AKI are critical for guiding timely interventions. This study evaluates the NephroCheck® score, based on Tissue inhibitor of metalloproteinases-2 (TIMP-2) and Insulin-like growth factor-binding protein 7 (IGFBP7) biomarkers. The primary objective was to assess its ability to predict AKI risk and AKI subtype within the first seven days of Intensive Care Unit (ICU) admission. Secondary objectives included evaluating its association with the need for renal replacement therapy (RRT) and overall ICU outcomes in a heterogeneous critical care population.
Methods |
This prospective, multicenter observational study included 455 ICU patients from five hospitals in Barcelona, Spain. Biomarker analysis was conducted on urine samples collected at admission, and AKI was classified according to the kidney Disease: Improving Global Outcomes (KDIGO) criteria. Patients were grouped by TIMP-2·IGFBP7 values and AKI subtypes. Data was analyzed using Stata version 18.0 (StataCorp, College Station, TX).
Results |
AKI occurred in 51% of patients; with 29% transient and 71% persistent. High TIMP-2·IGFBP7 (TIMP-2·IGFBP7 > 2.0) levels were significantly associated with AKI (OR 19.44; 95% CI [2.57–146.5], p = 0.004), persistent AKI (OR 4.3; 95% CI [1.61–11.41], p = 0.003), and RRT requirements (OR 3.93; 95% CI [1.34–11.47], p = 0.012). Patients with high TIMP-2·IGFBP7 had longer ICU stays, more severe AKI, increased RRT duration, and higher mortality rates. TIMP-2·IGFBP7 values correlated positively with ICU and in-hospital mortality and reduced 90-day survival.
Conclusion |
TIMP-2·IGFBP7 showed modest performance for early AKI detection, identifying RRT requirements and risk stratification in critically ill patients. While moderately effective for predicting outcomes, its role in differentiating transient from persistent AKI remains inconsistent. Further research is warranted to optimize TIMP-2·IGFBP7 guided interventions and explore its application in diverse AKI etiologies.
Le texte complet de cet article est disponible en PDF.Keywords : Critical care, Acute kidney injury, Renal replacement therapy, Biomarkers
Abbreviations : AKI, TIMP-2, IGFBP7, RRT, ICU, KDIGO, sCr, NGAL, APACHE II, SOFA, MV, GFR, ANOVA, SM, CKD, AUROC, CCL-14
Plan
Vol 16
Article 100111- 2026 Retour au numéro
Article précédent
- Extracorporeal circuit temperature gradient and hemodynamic instability during continuous renal replacement therapy: an observational study
- Lorna Fraire, Téo Keraron, Matthieu Chivot, Hodane Yonis, Guillaume Chazot, Mehdi Mezidi, Louis Chauvelot, Guillaume Deniel, Jean-Christophe Richard, Laurent Bitker
- A contemporary overview of severe community-acquired bacterial infections in pediatric intensive care units
- Michael Levy, Annelise Mary, Fleur Cour Andlauer, Jeremie Rousseaux, Lionel Berthomieu, Camille Brehin, Stephane Bechet, Montserrat Sierra-Colomina, Camille Aupiais, Francois Angoulvant, Elise Launay, Damien Dubois, Robert Cohen, Stephane Leteurtre, CAPRICE Study Group, Corinne Levy, Etienne Javouhey, Julien Baleine, Laurent Balu, Simon Barreault, Clémence Beauruelle, Emma Becuwe Gosselin, Matthieu Bendavid, Xavier Beretta Piccoli, Lionel Berthomieu, Stéphane Blanot, Stephane Bonacorsi, Yvonnick Boué, Noel Boussard, Gérald Boussicault, Camille Brehin, Alexandre Bretonneau, Arthur Charazac, Camille Chavy, Maryline Chomton Cailliez, Benoit Colomb, Fleur Cour Andlauer, Julie Cremninter, Etienne Darieux, Stephane Dauger, Alexandra David, Sandrine De Sampaio, Damien Dubois, Audrey Dupont, Jean Duval Destin, Aben Essid, Marion Favre, Fiona Bensoussan, Ghida Ghostine, Lucie Gibold, Marie-Laure Girardin, Chloe Hild, Sylvia Iacobelli, Charlotte Idier, Christophe Isnard, Benoit Jaulhac, Katy Jeannot, Julien Jegard, Mikael Jokic, Aurélie Labarre, Elise Launay, Cécile Le Brun, Michael Levy, Alain Lozniewski, Annelise Mary, Fabrice Michel, Christophe Milesi, Julie Missaire, Guillaume Mortamet, Simon Mounier, Audrey Mowendabeka, Jérôme Naudin, Anouk Navion, Mehdi Oualha, Naim Ouldali, Bruno Ozanne, Carla Parada-Rodrigues, Manon Passard, Quentin Pledran, Amandine Prenant, Pauline Ragon, Jérôme Rambaud, Sophie Reissier, Chloé Ribet, Claire Richarme, Barbara Ros, Jean-Michel Roué, Nicolas Roullet-Renoleau, Jérémie Rousseaux, Montserrat Sierra Colomina, Laurence Tabone, Muhamed-Kheir Taha, Asmaa Tazi, Aurore Thollot, Nicolas Traversier, Anne Tristan, Lucile Tzaroukian, Noemie Vanel, Diane Vareilles, Emmanuelle Varon, Laurent Villeneuve, Evelyne Werner, Arnaud Wiedemann, Amani Zaouali Dridi, Justine Zini, Charlie Zins
Bienvenue sur EM-consulte, la référence des professionnels de santé.